Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review

Abstract

ReuseUnless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version -refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website. TakedownIf you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. Technology Assessment Reports ForewordThe following abstracts are from publications produced by the Health Technology Assessment Programme in the United Kingdom. This is a national program of government-funded research that publishes over 40 reports every year. The overall aim of the program is to ensure that high-quality research information on the costs, effectiveness, and broader impact of health technologies is produced in the most efficient way for those who use, manage, and work in the National Health Service in England and Wales. Access to the full reports can be made free of charge on the HTA website http://www.ncchta.org http://www.ncchta.org A fully searchable CD-ROM containing the full text of all HTA reports is also available via the HTA website free of charge worldwide. Printed versions of the reports cost £20 (plus post and packing: free in the UK; £2 in Europe; £3 for Rest of the world). See website for details. Objectives: This study aimed to determine the costeffectiveness of influenza vaccination in people 65-74 years of age in the absence of comorbidity. Design: Primary research: randomized controlled trial. Setting: Primary care. Participants: People without risk factors for influenza or contraindications to vaccination were identified from twenty general practitioner (GP) practices in Liverpool in September 1999 and invited to participate in the study. There were 5,875 of 9,727 (60.4 percent) people 65-74 years of age identified as potentially eligible, and of these, 729 (12 percent) were randomized. Intervention: Participants were randomized to receive either influenza vaccine or placebo (ratio, 3:1), with all individuals receiving pneumococcal vaccine unless administered in the previous 10 years. Of the 729 people randomized, 552 received vaccine and 177 received placebo; 726 individuals were administered pneumococcal vaccine. Main outcome measures and methodology of economic evaluation: GP attendance with influenza-like illness (ILI) or pneumonia (primary outcome measure); or any respiratory symptoms; hospitalization with a respiratory illness; death; participant self-reported ILI; quality of life (QoL) measures at 2, 4, and 6 months poststudy vaccination; adverse reaction...

Outcome of children with hereditary tyrosinaemia following newborn screening

“…When last considered in the UK in 2004, HT1 did not meet the criteria for NBS as the sensitivity and specificity of screening methods available at that time were unclear and in addition there were uncertainties about the efficacy of available treatments and how time critical their introduction was 18. The four cases reported here were detected as an unintended consequence of conventional NBS for PKU.…”

Provision of information about newborn screening antenatally: a sequential exploratory mixed-methods project

“…A systematic review of published economic evaluations of NBS (reported in Chapter 6) identified five studies that included a cost associated with information provision related to NBS. [119][120][121][122][123] In the two identified studies relevant to the UK setting, 119,120 an incremental cost of providing information, based on the additional time that it would take a midwife to explain the additional tests being evaluated, was used (£0.30 119 and £0.40 120 ). Pandor et al 119 provided little information on how the cost they used was derived, but did refer to being informed by a consultation with a midwife.…”

“…In the UK-based analysis, Pandor et al 119 included a unit cost of £0.30 (2001 prices) per baby screened to account for the extra (incremental) time taken by a midwife to explain the test, although the actual length of additional time was not specified. This cost was identified through a consultation with a midwife.…”

“…21 NO. 55 Pandor et al 119,171 did not include an explicit value to quantify the impact of this 'harm' in their model even though the study described the need to provide information to reduce the anxiety that parents feel on the receipt of a false-positive result. The authors justified this omission by stating that any psychological disbenefits caused by screening would be far outweighed by the improvement in quality of life for children that a screening programme would bring.…”

Detection of Inborn Errors of Metabolism using Tandem Mass Spectrometry among High-risk Omani Patients

“…[1][2][3] At present, MS/MS is being used for screening and diagnosis of IEMs in newborns and sick infants in many clinical biochemical laboratories in the USA, Europe, Australia, Japan, and other countries. [4][5][6][7][8][9][10][11] SQUH is the main referral hospital for IEMs in Oman. An organized diagnostic service for IEMs for high-risk babies was established at SQUH in 1998.…”